Key facts
- This page summarizes Kevin Tang's Form 4 filing for Boundless Bio, Inc. (BOLD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Aug 2026, 16:16.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Additional SEC filing notes
Footnote F1
The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $10,046.70.
Footnote F2
The price reported herein is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.03. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the range set forth in Footnote 2.
Footnote F3
Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 887,715 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 642,589 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.